2016 American Transplant Congress
Safety and Efficacy of Ledipasvir/Sofosbuvir (LS) with or without Ribavirin (RBV) for Treatment of Recurrent Hepatitis C Infection Post-Liver Transplant.
Mulit-Organ Transplant Institute, Ochsner Medical Center, New Orleans, LA.
Background: Hepatitis C (HCV) is the most common indication for liver transplant in the United States representing more than 40% of all recipients. Availability of…2016 American Transplant Congress
Potential Biomarkers and Treatment for BK Virus Associated Nephropathy.
Background: BK polyomavirus assoiciated nephropathy (BKVAN) is one of the major complications in renal transplants, and is associated with significant fibrosis It is important to…2016 American Transplant Congress
Large Single-Center Experience of Sofosbuvir and Ledipasvir Therapy for the Treatment of Post-Liver Transplant Patients with Hepatitis C Virus.
Medicine, Emory University, Atlanta, GA.
Background/Aims: Controlled trials of direct acting antiviral therapy for Hepatitis C Virus (HCV) show impressive sustained virologic response (SVR) rates, but post-transplant data of sofosbuvir…2016 American Transplant Congress
Successful Treatment of Hepatitis C in Renal Transplant Recipients with Directly Acting Antiviral Agents.
Background: Hepatitis C infection (HCV) in kidney transplant (KTx) recipients has been shown to be a risk factor for decreased patient and allograft survival. With…2016 American Transplant Congress
Autologous BK-Specific T-Cell Lines in Kidney Transplant Recipients.
Background: More than 75% of the population has been exposed to BK polyomavirus and carries latent virus in the uroepithelium. Immunocompetent hosts are asymptomatic but…2016 American Transplant Congress
Incidence of Viral Infections in HLA-Sensitized Patients (HS Pts) Desensitized with IVIG + Rituximab (DES) Compared to Non-HS Pts Receiving Standard Immunosuppression.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: HS pts (PRA>50%, DSA+ at transplant) who are transplanted without DES represent a significant risk for antibody-mediated rejection. Prior to transplantation, HS pts require…2016 American Transplant Congress
Characterization of Resistant Cytomegalovirus in Lung Transplant Recipients in the Modern Era.
NewYork-Presbyterian Hospital, New York, NY.
Cytomegalovirus (CMV) remains a major cause of morbidity and mortality in lung transplant recipients (LTR) and the emergence of resistant CMV (rCMV) has increased. The…2016 American Transplant Congress
EBV Sero-Positivity Does Not Reduce the Risk for EBV Viremia and/or Post-Transplant Lymphoproliferative Disorder (PTLD) in Patients (Pts) Receiving Belatacept (CTLA4Ig).
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: CTLA4Ig is a novel immunosuppressive (IS) which acts through costimulatory blockade of T-cells and obviates the need for calcineurin inhibitor-based IS (CNI-IS). Despite benefits…2016 American Transplant Congress
Reduced-Dose Cidofovir (CID) and CMV-Hyperimmune Globulin (CMVIg) for Ganciclovir-Resistant Cytomegalovirus: Effective and Kidney Friendly.
Houston Methodist Hospital, Houston, TX.
Ganciclovir resistant (GR) CMV is associated with an aggressive disease course and substantial morbidity. Furthermore, treatment options such as foscarnet and cidofovir are incredibly nephrotoxic.…2015 American Transplant Congress
High Tolerability With Sofosbuvir-Based Direct-Acting Antiviral Therapy in Liver Transplant Recipients With Recurrent Hepatitis C
Background: Reports on efficacy, safety, and tolerability of sofobuvir-based antiviral regimens in liver transplant recipients with recurrent hepatitis C are limited. Methods: We performed a…
American Transplant Congress abstracts